LH
NEUTRAL
$259.57
Live
Labcorp Holdings Inc. · NYSE
Target $310.06
(+19.5%)
$234.16
52W Range
$293.72
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 29, 2026
Market cap
$21.39B
P/E
24.82
ROE
10.5%
Profit margin
6.3%
Debt/Equity
0.76
Dividend yield
1.11%
AI Analysis
AI-powered fundamental assessment
Confidence
85%
Labcorp (LH) presents a mixed profile with a stable Piotroski F-Score of 4/9 and a current price ($259.57) positioned between its defensive Graham Number ($157.1) and growth-based intrinsic value ($308.57). While the company demonstrates strong earnings growth (15.7% YoY) and a highly attractive forward P/E of 13.46, these fundamentals are countered by a bearish technical trend and significant insider selling. The long-term earnings track record is exceptional, but the lack of immediate momentum and mediocre health score suggest a neutral short-term outlook.
Key Strengths
Strong earnings growth of 15.7% YoY
Highly attractive Forward P/E of 13.46 compared to current P/E of 24.82
Exceptional earnings track record with consistent beats over 25 quarters
Manageable leverage with a Debt/Equity ratio of 0.76
Strong analyst consensus with a target price of $310.06
Key Risks
Bearish insider sentiment with 7 sell transactions and 0 buys
Technical trend is completely bearish (0/100)
Modest revenue growth (5.6%) lagging behind earnings growth
Piotroski F-Score of 4/9 indicates only stable, not strong, financial health
Current price trades at a significant premium to the Graham defensive value
AI Fair Value Estimate
Based on comprehensive analysis
$285.0
+9.8% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
62
Strong
60
70
90
50
40
AI Verdict
Neutral-Bullish
Key drivers: Strong EPS growth, Attractive Forward P/E, Bearish Insider Activity, Weak Technicals
Confidence
85%
Value
60/100
Ref P/E 24.82, Forward P/E 13.46, Graham Number $157.1
Positives
- Low Forward P/E
- PEG ratio of 1.09 suggests fair valuation relative to growth
Watchpoints
- Price is well above Graham Number ($157.1)
Future
70/100
Ref Growth rates and Analyst Targets
Positives
- 15.7% YoY Earnings Growth
- Positive analyst target price ($310.06)
Watchpoints
- Slow revenue growth (5.6%)
Past
90/100
Ref Historical earnings surprises
Positives
- Consistent history of beating earnings estimates over 25 quarters
Watchpoints
No urgent risks highlighted.
Health
50/100
Ref Piotroski F-Score 4/9
Positives
- Current Ratio of 1.42
- Debt/Equity of 0.76
Watchpoints
- Piotroski F-Score of 4/9 is only 'Stable'
Dividend
40/100
Ref Yield 1.11%, Payout 27.53%
Positives
- Low payout ratio (27.53%) indicates high sustainability
Watchpoints
- Low dividend yield (1.11%)
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$259.57
Analyst Target
$310.06
Upside/Downside
+19.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LH and closest competitors.
Updated 2026-04-28
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LH
Labcorp Holdings Inc.
Primary
|
+18.8% | +38.2% | +14.3% | +0.5% | -1.5% | -5.1% |
|
CNC
Centene Corporation
Peer
|
-26.9% | -36.9% | -26.9% | +31.2% | +35.9% | +13.6% |
|
ROIV
Roivant Sciences Ltd.
Peer
|
+203.5% | +236.3% | +193.9% | +72.8% | +7.3% | +5.7% |
|
DGX
Quest Diagnostics Incorporated
Peer
|
+63.6% | +42.2% | +13.6% | +8.7% | +0.3% | +0.6% |
|
BNTX
BioNTech SE
Peer
|
-20.9% | -28.6% | -2.4% | -9.9% | -17.3% | +2.4% |
LH
Labcorp Holdings Inc.
Primary
5Y
+18.8%
3Y
+38.2%
1Y
+14.3%
6M
+0.5%
1M
-1.5%
1W
-5.1%
CNC
Centene Corporation
Peer
5Y
-26.9%
3Y
-36.9%
1Y
-26.9%
6M
+31.2%
1M
+35.9%
1W
+13.6%
ROI
Roivant Sciences Ltd.
Peer
5Y
+203.5%
3Y
+236.3%
1Y
+193.9%
6M
+72.8%
1M
+7.3%
1W
+5.7%
DGX
Quest Diagnostics Incorporated
Peer
5Y
+63.6%
3Y
+42.2%
1Y
+13.6%
6M
+8.7%
1M
+0.3%
1W
+0.6%
BNT
BioNTech SE
Peer
5Y
-20.9%
3Y
-28.6%
1Y
-2.4%
6M
-9.9%
1M
-17.3%
1W
+2.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
24.82
Forward P/E
13.46
PEG Ratio
1.09
P/B Ratio
2.48
P/S Ratio
1.53
EV/Revenue
1.96
EV/EBITDA
12.5
Market Cap
$21.39B
Profitability
Profit margins and return metrics
Profit Margin
6.28%
Operating Margin
10.55%
Gross Margin
28.76%
ROE
10.51%
ROA
5.12%
Growth
Revenue and earnings growth rates
Revenue Growth
+5.6%
Earnings Growth
+15.7%
Q/Q Revenue Growth
+5.6%
Q/Q Earnings Growth
+14.9%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.76
Moderate
Current Ratio
1.42
Good
Quick Ratio
0.99
Poor
Cash/Share
$6.46
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$3.5B
Gross Margin
28.2%
Op. Margin
10.9%
Net Margin
4.7%
Total Assets
$18.4B
Liabilities
$9.8B
Equity
$8.6B
Debt/Equity
1.13x
Operating CF
$0.6B
CapEx
$-0.1B
Free Cash Flow
$0.5B
FCF Yield
80%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-17
$4.07
+3.2% surprise
2025-10-28
$4.18
+1.0% surprise
2025-07-24
$4.35
+4.1% surprise
Healthcare Sector Comparison
Comparing LH against 566 companies in the Healthcare sector
(36 bullish, 169 neutral, 361 bearish)
P/E Ratio
24.82
This Stock
vs
74.01
Sector Avg
-66.5%
(Discount)
Return on Equity (ROE)
10.51%
This Stock
vs
-87.13%
Sector Avg
-112.1%
(Below Avg)
Profit Margin
6.28%
This Stock
vs
-16.04%
Sector Avg
-139.2%
(Weaker)
Debt to Equity
0.76
This Stock
vs
2.64
Sector Avg
-71.4%
(Less Debt)
Revenue Growth
5.6%
This Stock
vs
122.93%
Sector Avg
-95.4%
(Slower)
Current Ratio
1.42
This Stock
vs
4.46
Sector Avg
-68.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LH
Labcorp Holdings Inc.
|
NEUTRAL | $21.39B | 24.82 | 10.5% | 6.3% | $259.57 | |
|
CNC
Centene Corporation
|
BEARISH | $21.39B | - | -28.7% | -3.8% | $43.5 | Compare |
|
ROIV
Roivant Sciences Ltd.
|
NEUTRAL | $21.35B | - | -19.1% | -% | $29.83 | Compare |
|
DGX
Quest Diagnostics Incorporated
|
NEUTRAL | $21.73B | 21.69 | 14.5% | 9.1% | $196.27 | Compare |
|
BNTX
BioNTech SE
|
BEARISH | $22.34B | - | -5.9% | -39.6% | $88.88 | Compare |
LH
Labcorp Holdings Inc.
NEUTRAL
Mkt Cap
$21.4B
P/E
24.8
ROE
10.5%
Price
$259.57
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-27 | MELTZER JONATHAN C | Officer | Sale | 839 | $224,055 |
| 2026-03-27 | WILKINSON PETER J | Officer | Sale | 1,633 | $436,093 |
| 2026-03-26 | SUMMY AMY B | Officer | Stock Award | 3,994 | - |
| 2026-03-26 | BAILEY MEGAN D | Officer | Stock Award | 1,184 | - |
| 2026-03-26 | OYEGUNWA AKINBOLADE | Chief Technology Officer | Stock Award | 1,340 | - |
| 2026-03-26 | MELTZER JONATHAN C | Officer | Stock Award | 2,388 | - |
| 2026-03-26 | KYLE KATHRYN W | Officer | Stock Award | 1,584 | - |
| 2026-03-26 | VAUGHN BRYAN T | Officer | Stock Award | 1,584 | - |
| 2026-03-26 | WILKINSON PETER J | Officer | Stock Award | 2,388 | - |
| 2026-03-26 | VAN DER VAART SANDRA DILLARD | Officer | Stock Award | 6,382 | - |
| 2026-03-26 | CAVENEY BRIAN J | Officer | Stock Award | 11,290 | - |
| 2026-03-26 | SCHROEDER MARK S | Chief Operating Officer | Stock Award | 12,272 | - |
| 2026-03-26 | SCHECHTER ADAM H | Chief Executive Officer | Stock Award | 58,470 | - |
| 2026-03-26 | GRAHAM ANITA Z | Officer | Stock Award | 6,604 | - |
| 2026-03-03 | SCHECHTER ADAM H | Chief Executive Officer | Sale | 8,705 | $2,437,047 |
MELTZER JONATHAN C
Officer
2026-03-27
839 shares
·
$224,055
WILKINSON PETER J
Officer
2026-03-27
1,633 shares
·
$436,093
SUMMY AMY B
Officer
2026-03-26
3,994 shares
BAILEY MEGAN D
Officer
2026-03-26
1,184 shares
OYEGUNWA AKINBOLADE
Chief Technology Officer
2026-03-26
1,340 shares
MELTZER JONATHAN C
Officer
2026-03-26
2,388 shares
KYLE KATHRYN W
Officer
2026-03-26
1,584 shares
VAUGHN BRYAN T
Officer
2026-03-26
1,584 shares
WILKINSON PETER J
Officer
2026-03-26
2,388 shares
VAN DER VAART SANDRA DILLARD
Officer
2026-03-26
6,382 shares
CAVENEY BRIAN J
Officer
2026-03-26
11,290 shares
SCHROEDER MARK S
Chief Operating Officer
2026-03-26
12,272 shares
SCHECHTER ADAM H
Chief Executive Officer
2026-03-26
58,470 shares
GRAHAM ANITA Z
Officer
2026-03-26
6,604 shares
SCHECHTER ADAM H
Chief Executive Officer
2026-03-03
8,705 shares
·
$2,437,047
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
DEF 14A
8-K
8-K
10-K
8-K
8-K
8-K
8-K
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
17 analysts
Evercore ISI Group
2026-04-08
Outperform
Outperform
Piper Sandler
2026-02-24
Neutral
Neutral
JP Morgan
2026-02-18
Overweight
Overweight
Baird
2026-02-18
Outperform
Outperform
JP Morgan
2026-02-06
Overweight
Overweight
JP Morgan
2025-11-07
Overweight
Overweight
Past News Coverage
Recent headlines mentioning LH from our newsroom.
Newest → oldest
No matching news yet.